Key result
L-thyroxin therapy linked to improved FMD in women across all severities of hypothyroidism.
Why the study?
Hypothyroidism promotes premature subclinical atherosclerosis characterized by endothelial dysfunction and increased arterial stiffness, but its presence and evolution under therapy need assessment.
Does L-thyroxin therapy improve endothelial dysfunction and arterial stiffness in young hypothyroid women?
Population
56 young hypothyroid women without cardiovascular pathology or atherosclerosis risk factors
Comparison
Hypothyroid patients before and after L-thyroxin therapy vs healthy controls
Design
Cohort study using three noninvasive methods to assess endothelial dysfunction
Authors
Loading...
Noninvasive ED assessment may inform hypothyroidism management; leaves open whether therapy reverses changes in larger trials.
Cohort (n=71)
No
Does L-thyroxin therapy improve endothelial dysfunction and arterial stiffness in young hypothyroid women?
p-value: p=<0.0001
L-thyroxin therapy improves endothelial dysfunction and arterial stiffness in young hypothyroid women prior to the onset of structural atherosclerotic changes.
Tudoran et al. (2015) conducted a cohort in Hypothyroidism (n=71). L-thyroxin vs. Baseline (pre-treatment) and healthy controls was evaluated on Flow-mediated vasodilatation (FMD) index (p=<0.0001). L-thyroxin therapy significantly improved endothelial dysfunction, measured by flow-mediated vasodilatation, in women with hypothyroidism across all severity subgroups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: